Crucell N.V. and Sanofi Pasteur have restructured their partnership, following last year’s acquisition of Shantha Biotechnics by Sanofi. Crucell will waive its right to terminate an existing license agreement between Crucell Switzerland and Shantha for the development of pediatric vaccines, based on Hemophilus influenzae b. This termination right was triggered by the change of control at Shantha. Sanofi Pasteur will return the commercial rights it held under an exclusive license agreement for...